FILSPARI's approval in FSGS creates a new standard of care and first-mover advantage in a rare disease with no prior approved treatments. Traders should monitor commercial ramp-up and potential pricing power, while watching for competitive responses. Consider this a major value inflection given the expanded addressable market.
Price Chart
Executive Summary
Travere Therapeutics (TVTX) announced FDA approval of FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8+ with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks the first and only FDA-approved treatment for FSGS, expanding FILSPARI's label beyond IgA nephropathy.
Key Facts
- FDA approved FILSPARI for FSGS without nephrotic syndrome in patients aged 8 and older
- FILSPARI is the first and only FDA-approved treatment for FSGS
- Approval expands FILSPARI's label beyond IgA nephropathy into a second rare kidney disease
- Phase 3 DUPLEX study showed 48% reduction in proteinuria vs 27% for irbesartan in non-nephrotic FSGS patients
- Company estimates U.S. addressable population exceeds 30,000 individuals with FSGS without nephrotic syndrome
Financial Impact
Potential blockbuster expansion: FILSPARI now addresses >30,000 additional U.S. FSGS patients without nephrotic syndrome, significantly expanding its commercial opportunity beyond IgA nephropathy
Risk Factors
- Commercial execution risk in launching and marketing to a new patient population
- Potential payer reimbursement challenges for a high-cost rare disease drug
- Safety profile monitoring in broader patient population
- Future competition from emerging FSGS therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001438533-26-000032 |
| Document: 0001438533-26-000032-index-headers.html | 0001438533-26-000032 |
| Document: 0001438533-26-000032-index.html | 0001438533-26-000032 |
| Document: 0001438533-26-000032.txt | 0001438533-26-000032 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 9, 2026 12w ago | 8-K | $56.59 $61.32 | ▲ +8.36% | ▲ +5.93% | $56.93 (+0.60%) |
Jun 16, 2026 15w ago | Insider Cluster | $54.14 $55.28 | ▲ +2.11% | ▲ +0.79% | $56.93 (+5.15%) |
Jun 16, 2026 15w ago | 8-K | $54.14 $55.28 | ▲ +2.11% | ▲ +0.79% | $56.93 (+5.15%) |
Jun 12, 2026 16w ago | 144 | $52.04 $56.59 | ▲ +8.74% | ▲ +6.96% | $56.93 (+9.40%) |
Jun 2, 2026 17w ago | 8-K | $42.96 $56.34 | ▲ +31.15% | ▲ +32.71% | $56.93 (+32.52%) |
May 15, 2026 20w ago | 144 | $42.59 $53.80 | ▲ +26.32% | ▲ +24.20% | $56.93 (+33.67%) |
May 5, 2026 21w ago | 144 | $44.76 $45.20 | ▲ +0.98% | ▼ −1.80% | $56.93 (+27.19%) |
May 4, 2026 21w ago | 144 | $44.80 $42.96 | ▼ −4.11% | ▼ −9.06% | $56.93 (+27.08%) |
May 1, 2026 22w ago | Insider Cluster | $44.12 $45.04 | ▼ −2.09% | ▲ +3.20% | $56.93 (−29.03%) |
Apr 15, 2026 24w ago | 144 | $40.95 $42.84 | ▲ +4.62% | ▼ −1.43% | $56.93 (+39.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access